Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation

Trial Profile

Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Apr 2016 Planned End Date changed from 1 Aug 2020 to 1 Aug 2018 according to to ClinicalTrials.gov record.
    • 29 Mar 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
    • 13 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top